PAR:VETO
Vetoquinol S.A. · PAR · Healthcare · EUR · FY for 2025
Figures on this page computed 2026-11-08 12:42 UTC
Last close
n/aEUR
Market data
17.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- computed
- Computed from the filing for 2025
14.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
10.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
9.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.03Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
1.0%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- EUR
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
What it sells, to whom
lens 8 of 9The filer tagged nothing for this, so there is nothing filed to draw.
Nothing is drawn in its place. The other lenses are unaffected.
This filer tagged no segment and no customer.